Cargando…

Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19

The precise diagnosis of COVID-19 is of outmost importance in order to effectively treat patients and prevent SARS-CoV-2 transmission. Herein, we evaluated the sensitivity and specificity of the COVID-19 Antigen Detection Kit (Colloidal Gold—CG) compared with PCR in nasopharyngeal and nasal samples....

Descripción completa

Detalles Bibliográficos
Autores principales:	Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Skvarč, Miha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229208/ https://www.ncbi.nlm.nih.gov/pubmed/34070844 http://dx.doi.org/10.3390/diagnostics11060995

Ejemplares similares

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Receptor-Binding-Domain-Specific B Cell Responses Induced by mRNA Immunization against SARS-CoV-2
por: Geropeppa, Maria, et al.
Publicado: (2023)

The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma
por: Giannakoulas, Nikolaos, et al.
Publicado: (2021)

BCMA in Multiple Myeloma—A Promising Key to Therapy
por: Kleber, Martina, et al.
Publicado: (2021)

Use of Immunochromatographic SARS-CoV-2 Antigen Testing in Eight Long-Term Care Facilities for the Elderly
por: Ifko, Martina, et al.
Publicado: (2021)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study
por: Zirou, Christina, et al.
Publicado: (2023)

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection
por: Malandrakis, Panagiotis, et al.
Publicado: (2020)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
por: Terpos, Evangelos, et al.
Publicado: (2018)

Evaluation of Analytical Performance of Seven Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus
por: Eshghifar, Nahal, et al.
Publicado: (2021)

Comparison of analytical sensitivity of the eight rapid antigen detection kits for detecting SARS-CoV-2 virus
por: Mak, Gannon C.K., et al.
Publicado: (2021)

Evaluation of Rapid Antigen Detection Kits for Detection of SARS-CoV-2 B.1.1.529
por: Mak, Gannon C. K., et al.
Publicado: (2022)

Development of an Antigen Detection Kit Capable of Discriminating the Omicron Mutants of SARS-CoV-2
por: Li, Jiaji, et al.
Publicado: (2023)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
por: Liatsou, Efstathia, et al.
Publicado: (2023)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus
por: Mak, Gannon CK, et al.
Publicado: (2020)

Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2
por: Mak, Gannon C.K., et al.
Publicado: (2021)

Evaluation of rapid antigen detection kits for detection of SARS-CoV-2 B.1.617.2 virus
por: Mak, Gannon CK, et al.
Publicado: (2022)

Comparative Analysis of SARS-CoV-2 Detection Kits
por: Mulahuseinovic, Naida, et al.
Publicado: (2022)

Rapid antigen detection kit for the diagnosis of SARS-CoV-2 - are we missing asymptomatic patients?
por: Kanaujia, Rimjhim, et al.
Publicado: (2021)

A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination
por: Liu, Jia, et al.
Publicado: (2021)

Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
por: Filippatos, Charalampos, et al.
Publicado: (2023)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
por: Orologas-Stavrou, Nikolaos, et al.
Publicado: (2020)

Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection
por: Rosati, Margherita, et al.
Publicado: (2021)

Detection of SARS-CoV-2 omicron variants by immunochromatographic kit
por: Oshiro, Satoshi, et al.
Publicado: (2023)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background
por: Papanota, Aristea-Maria, et al.
Publicado: (2021)

Comparison of analytical sensitivity of SARS-CoV-2 molecular detection kits
por: Yang, Jing, et al.
Publicado: (2021)

Evaluation of multiple RTPCR kits for detection of SARS CoV-2 RNA
por: Arora, Ananya, et al.
Publicado: (2021)

Colloidal gold immunochromatographic assay (GICA) is an effective screening method for identifying detectable anti-SARS-CoV-2 neutralizing antibodies
por: Li, Xinjie, et al.
Publicado: (2021)

Detecting spread of SARS‐CoV‐2 variants using PowerChek SARS‐CoV‐2 S‐gene mutation detection kit
por: Kim, Hyun Jin, et al.
Publicado: (2022)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_39c38uit4mpccr0ccu8fcvg1kl